Boehringer Ingelheim Exercises Option on Second Hepatic...
Business Wire IndiaBoehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelhe...